Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

• Rikio Suzuki ,

  Contributed equally to this work with: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada

  Affiliations Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America, Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan

  ⨯
• Shohei Kikuchi ,

  Contributed equally to this work with: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Takeshi Harada ,

  Contributed equally to this work with: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Naoya Mimura,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Jiro Minami,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Hiroto Ohguchi,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Yasuhiro Yoshida,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Morihiko Sagawa,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Gullu Gorgun,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Diana Cirstea,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Francesca Cottini,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Jana Jakubikova,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Yu-Tzu Tai,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Dharminder Chauhan,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Paul G. Richardson,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Nikhil Munshi,

  Affiliation VA Boston Healthcare System, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• Kiyoshi Ando,

  Affiliation Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan

  ⨯
• Teruhiro Utsugi,

  Affiliation Tsukuba Research Center, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan

  ⨯
• Teru Hideshima,

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
•  [ ... ],
• Kenneth C. Anderson

  * E-mail: kenneth_anderson@dfci.harvard.edu

  Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

  ⨯
• [ view all ]
• [ view less ]